OncoMed Pharma (OMED) Reports In-Line Q3 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/2/2026
- Nasdaq hits record high after softer jobs data tempers rate-hike bets
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- DataMeds AI's Corexa Pharmacy tops $1M in monthly revenue
- Equities rebound to close higher as surging Treasury yields recede
- Twilio, Vylor set to join S&P 500 as index reshuffles members
- onsemi cuts Synaptics deal price to $5.7B after rival bid
- Wells Fargo names 13 stocks as overweight tactical ideas
OncoMed Pharmaceuticals Reports Third Quarter 2016 Financial Results
November 1, 2016 4:07 PM EDTEnds Quarter with $207 Million Cash Enrollment Complete in Phase 2 Trials for Demcizumab and Tarextumab;On Track for Data in 1H 2017
OncoMed Management to Host Conference Call/Webcast this Afternoon at 4:30 p.m. ET/1:30 p.m. PT
REDWOOD CITY, Calif., Nov. 01, 2016 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (Nasdaq: OMED), a clinical-stage company focused on discovering and developing novel anti-cancer stem cell and immuno-oncology therapeutics, today reported third quarter financial results. As of September 30, 2016, cash, cash equivalents and short-term investments totaled $207.6 million.Â
OncoMed remains focused on... More
